MedCap Inkomsten in het verleden

Verleden criteriumcontroles 5/6

MedCap is de winst gegroeid met een gemiddeld jaarlijks percentage van 32.4%, terwijl de Life Sciences industrie de winst jaarlijks groeide met 28.5%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 19.7% per jaar. Het rendement op eigen vermogen van MedCap is 19.1%, en het heeft een nettomarge van 12.7%.

Belangrijke informatie

32.4%

Groei van de winst

31.2%

Groei van de winst per aandeel

Life Sciences Groei van de industrie31.8%
Inkomstengroei19.7%
Rendement op eigen vermogen19.1%
Nettomarge12.7%
Volgende winstupdate31 Jan 2025

Recente prestatie-updates uit het verleden

Recent updates

MedCap AB (publ)'s (STO:MCAP) Earnings Haven't Escaped The Attention Of Investors

Oct 18
MedCap AB (publ)'s (STO:MCAP) Earnings Haven't Escaped The Attention Of Investors

Estimating The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)

Jun 06
Estimating The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)

MedCap AB (publ) (STO:MCAP) Stocks Shoot Up 33% But Its P/E Still Looks Reasonable

May 21
MedCap AB (publ) (STO:MCAP) Stocks Shoot Up 33% But Its P/E Still Looks Reasonable

Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?

May 04
Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?

MedCap AB (publ)'s (STO:MCAP) P/E Is Still On The Mark Following 25% Share Price Bounce

Feb 15
MedCap AB (publ)'s (STO:MCAP) P/E Is Still On The Mark Following 25% Share Price Bounce

Is Now The Time To Put MedCap (STO:MCAP) On Your Watchlist?

Dec 21
Is Now The Time To Put MedCap (STO:MCAP) On Your Watchlist?

Do MedCap's (STO:MCAP) Earnings Warrant Your Attention?

May 06
Do MedCap's (STO:MCAP) Earnings Warrant Your Attention?

These 4 Measures Indicate That MedCap (STO:MCAP) Is Using Debt Safely

Nov 23
These 4 Measures Indicate That MedCap (STO:MCAP) Is Using Debt Safely

We Ran A Stock Scan For Earnings Growth And MedCap (STO:MCAP) Passed With Ease

Sep 21
We Ran A Stock Scan For Earnings Growth And MedCap (STO:MCAP) Passed With Ease

Does MedCap (STO:MCAP) Deserve A Spot On Your Watchlist?

Apr 29
Does MedCap (STO:MCAP) Deserve A Spot On Your Watchlist?

MedCap (STO:MCAP) Seems To Use Debt Rather Sparingly

Feb 01
MedCap (STO:MCAP) Seems To Use Debt Rather Sparingly

Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?

Aug 03
Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?

Does MedCap (STO:MCAP) Have A Healthy Balance Sheet?

May 27
Does MedCap (STO:MCAP) Have A Healthy Balance Sheet?

Here's Why I Think MedCap (STO:MCAP) Is An Interesting Stock

Apr 07
Here's Why I Think MedCap (STO:MCAP) Is An Interesting Stock

Imagine Holding MedCap (STO:MCAP) Shares While The Price Zoomed 558% Higher

Mar 15
Imagine Holding MedCap (STO:MCAP) Shares While The Price Zoomed 558% Higher

Have Insiders Been Selling MedCap AB (publ) (STO:MCAP) Shares?

Feb 26
Have Insiders Been Selling MedCap AB (publ) (STO:MCAP) Shares?

MedCap (STO:MCAP) Could Easily Take On More Debt

Feb 08
MedCap (STO:MCAP) Could Easily Take On More Debt

Declining Stock and Solid Fundamentals: Is The Market Wrong About MedCap AB (publ) (STO:MCAP)?

Jan 22
Declining Stock and Solid Fundamentals: Is The Market Wrong About MedCap AB (publ) (STO:MCAP)?

Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?

Jan 07
Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?

MedCap (STO:MCAP) Is Growing Earnings But Are They A Good Guide?

Dec 22
MedCap (STO:MCAP) Is Growing Earnings But Are They A Good Guide?

If You Had Bought MedCap (STO:MCAP) Stock Five Years Ago, You Could Pocket A 663% Gain Today

Dec 08
If You Had Bought MedCap (STO:MCAP) Stock Five Years Ago, You Could Pocket A 663% Gain Today

Are Insiders Selling MedCap AB (publ) (STO:MCAP) Stock?

Nov 23
Are Insiders Selling MedCap AB (publ) (STO:MCAP) Stock?

Opbrengsten en kosten

Hoe MedCap geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

OM:MCAP Opbrengsten, kosten en inkomsten (SEK Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 241,8012286740
30 Jun 241,7532146550
31 Mar 241,6812036240
31 Dec 231,6001726010
30 Sep 231,4661505620
30 Jun 231,3431495230
31 Mar 231,2411234860
31 Dec 221,1241184440
30 Sep 221,0561184190
30 Jun 221,0171074100
31 Mar 229671023940
31 Dec 21926973850
30 Sep 21896763750
30 Jun 21869643590
31 Mar 21845673390
31 Dec 20828633290
30 Sep 20802553260
30 Jun 20786533170
31 Mar 20763473080
31 Dec 19757552940
30 Sep 19734432880
30 Jun 19740412910
31 Mar 19727322970
31 Dec 18709242980
30 Sep 18716142860
30 Jun 1868982780
31 Mar 18660102680
31 Dec 1761772610
31 Oct 17779112980
31 Jul 1780233010
30 Apr 1785302990
31 Jan 1790152910
31 Oct 16897102760
31 Jul 16874192580
30 Apr 16818202390
31 Jan 16817182320
31 Oct 15818172260
31 Jul 1582582280
30 Apr 1585592280
31 Jan 1589192260
31 Oct 14913152210
31 Jul 14910212130
30 Apr 14827232030
31 Jan 14651181850

Kwaliteitswinsten: MCAP heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (12.7%) MCAP } zijn hoger dan vorig jaar (10.3%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van MCAP is de afgelopen 5 jaar aanzienlijk gegroeid met 32.4% per jaar.

Versnelling van de groei: De winstgroei van MCAP over het afgelopen jaar ( 51.7% ) overtreft het 5-jarig gemiddelde ( 32.4% per jaar).

Winst versus industrie: De winstgroei MCAP over het afgelopen jaar ( 51.7% ) overtrof de Life Sciences -sector 36%.


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 19.1% ) van MCAP wordt als laag beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden